U.S. patent application number 11/747722 was filed with the patent office on 2009-09-10 for novel g protein-coupled receptor.
Invention is credited to Sultan Ahmad, Denis Banville, Yves Fortin, Paola Lembo, Dajan O'Donnell, Shi-Hsiang Shen.
Application Number | 20090226932 11/747722 |
Document ID | / |
Family ID | 20409539 |
Filed Date | 2009-09-10 |
United States Patent
Application |
20090226932 |
Kind Code |
A1 |
Ahmad; Sultan ; et
al. |
September 10, 2009 |
Novel G Protein-Coupled Receptor
Abstract
The present invention is directed to novel G protein-coupled
receptors that are found predominantly in the dorsal root ganglia.
The invention encompasses both the receptor proteins as well as
nucleic acids encoding the proteins. In addition, the present
invention is directed to methods and compositions which utilize the
receptors.
Inventors: |
Ahmad; Sultan; (St. Laurent,
CA) ; Banville; Denis; (Ste-Dorothee, CA) ;
Fortin; Yves; (Montreal, CA) ; Lembo; Paola;
(St. Laurent, CA) ; O'Donnell; Dajan; (St.
Laurent, CA) ; Shen; Shi-Hsiang; (Beaconsfield,
CA) |
Correspondence
Address: |
Pepper Hamilton LLP
400 Berwyn Park, 899 Cassatt Road
Berwyn
PA
19312-1183
US
|
Family ID: |
20409539 |
Appl. No.: |
11/747722 |
Filed: |
May 11, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10747702 |
Dec 30, 2003 |
7217693 |
|
|
11747722 |
|
|
|
|
09254227 |
Mar 3, 1999 |
6696257 |
|
|
PCT/SE98/02348 |
Dec 16, 1998 |
|
|
|
10747702 |
|
|
|
|
Current U.S.
Class: |
435/7.2 ;
435/320.1; 435/325; 435/4; 436/501; 530/350; 536/23.1 |
Current CPC
Class: |
C07K 14/705
20130101 |
Class at
Publication: |
435/7.2 ;
530/350; 536/23.1; 435/320.1; 435/325; 436/501; 435/4 |
International
Class: |
G01N 33/53 20060101
G01N033/53; C07K 14/00 20060101 C07K014/00; C07H 21/00 20060101
C07H021/00; C12N 15/63 20060101 C12N015/63; C12N 5/00 20060101
C12N005/00; C12Q 1/00 20060101 C12Q001/00 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 22, 1997 |
SE |
9704836-7 |
Claims
1-42. (canceled)
43. A substantially pure protein, wherein the protein comprises the
amino acid sequence SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID
NO:11, or SEQ ID NO:13.
44. A substantially pure polynucleotide encoding a protein of claim
43.
45. The polynucleotide of claim 44 wherein the polynucleotide
comprises the nucleotide sequence SEQ ID NO:6, SEQ ID NO:8, SEQ ID
NO:10, SEQ ID NO:12, or SEQ ID NO:14.
46. A vector comprising the polynucleotide of claim 44.
47. A host cell transformed with a vector of claim 46.
48. A recombinant protein produced by the host cell of claim
47.
49. A method for assaying a test compound for its ability to
inhibit the binding of a ligand to human dorsal root receptor-2
(hDRR-2), human dorsal root receptor-3 (hDRR-3), human dorsal root
receptor-4 (hDRR-4), human dorsal root receptor-5 (hDRR-5), or
human dorsal root receptor-6 (hDRR-6) comprising: a) incubating a
source containing hDRR-2 according to SEQ ID NO:5, hDRR-3 according
to SEQ ID NO:7, hDRR-4 according to SEQ ID NO:9, hDRR-5 according
to SEQ ID NO:11, or hDRR-6 according to SEQ ID NO:13, but
substantially free of other G protein coupled receptors, with: i) a
ligand known to bind to hDRR-2 according to SEQ ID NO:5, hDRR-3
according to SEQ ID NO:7, hDRR-4 according to SEQ ID NO:9, hDRR-5
according to SEQ ID NO:11, or hDRR-6 according to SEQ ID NO:13; and
ii) the test compound; and b) determining the extent to which the
ligand binding is displaced by the test compound.
50. A method for determining if a test compound is an agonist of
human DRR-2, human DRR-3, human DRR-4, human DRR-5, or human DRR-6,
comprising: a) determining the ability of the test compound to bind
to human DRR-2, human DRR-3, human DRR-4, human DRR-5, or human
DRR-6; and b) determining whether the test compound causes a
statistically significant increase in either intracellular adenyl
cyclase activity or the intracellular concentration of calcium.
51. A method for determining if a test compound is an antagonist of
human DRR-2, human DRR-3, human DRR-4, human DRR-5, or human DRR-6,
comprising: a) incorporating a DNA molecule encoding human DRR-2,
human DRR-3, human DRR-4, human DRR-5, or human DRR-6, into an
expression vector so that it is operably linked to a promoter; b)
transfecting the expression vector into a host cell; c) selecting
cells transfected in step b) that have constitutively activated
DRR-1 receptors as evidenced by either: i) a statistically
significant increase in intracellular adenyl cyclase activity; or
ii) a statistically significant increase in intracellular calcium
concentration; d) determining the binding of the test compound to
the cells selected in step c); and e) determining if the test
compound causes a statistically significant decrease in either the
adenyl cyclase activity or the calcium concentration relative to
control cells not contacted with the test compound.
Description
FIELD OF THE INVENTION
[0001] The present invention is in the general field of biological
receptors and the various uses that can be made of such receptors.
More specifically, the invention relates to nucleic acids encoding
novel G protein-coupled receptors and to the receptors per se.
BACKGROUND AND PRIOR ART
[0002] G protein-coupled receptors (GPCRs) constitute a family of
proteins sharing a common structural organization characterized by
an extracellular N-terminal end, seven hydrophobic alpha helices
putatively constituting transmembrane domains and an intracellular
C-terminal domain. GPCRs bind a wide variety of ligands that
trigger intracellular signals through the activation of transducing
G proteins (Caron, et al., Rec. Prog. Horm. Res. 48:277-290 (1993);
Freedman et al., Rec. Prog. Horm. Res. 51:319-353 (1996)).
[0003] More than 300 GPCRs have been cloned thus far and it is
generally assumed that there exist well over 1000 such receptors.
Mechanistically, approximately 50-60% of all clinically relevant
drugs act by modulating the functions of various GPCRs (Cudermann,
et al., J. Mol. Med. 73:51-63 (1995)). Of particular interest are
receptors located in dorsal root ganglia. This region of the
central nervous system is densely innervated with primary or
afferent sensory neurons involved in the transmission, modulation
and sensation of pain. Thus, receptors from this region may be used
in assays for the identification of new agents for anesthesia and
analgesia
SUMMARY OF THE INVENTION
[0004] The present invention is based upon the discovery of a novel
G protein-coupled receptor which is distinct from previously
reported receptors in terms of structure and in being expressed
preferentially in dorsal root ganglia. One dorsal root receptor
(DRR) has been isolated and sequenced from the rat and six from the
human. The rat receptor was given the designation rDRR-1 and its
amino acid sequence is shown as SEQ ID NO:1. The human receptors
were designated as
hDRR-1 (SEQ ID NO:3); hDRR-2 (SEQ ID NO:5); hDRR-3 (SEQ ID NO:7).
hDRR-4 (SEQ ID NO:9); hDRR-5 (SEQ ID NO:11); and hDRR-6 (SEQ ID
NO:13).
[0005] Unless otherwise specified, the term "DRR" as used herein
refers to all of the receptors from both human and rat.
[0006] In its first aspect, the invention is directed to proteins,
except as existing in nature, comprising the amino acid sequence
consisting functionally of a rat or human DRR as shown in SEQ ID
NO:1, 3, 5, 7, 9, 11, or 13. The term "consisting functionally of"
is intended to include any receptor protein whose sequence has
undergone additions, deletions or substitutions which do not
substantially alter the functional characteristics of the receptor.
Thus, the invention encompasses proteins having exactly the same
amino acid sequence as shown in the sequence listing, as well as
proteins with differences that are not substantial as evidenced by
their retaining the basic, qualitative binding properties of the
DRR receptor. The invention further encompasses substantially pure
proteins consisting essentially of a DRR amino acid sequence,
antibodies that bind specifically to a DRR (i.e. that have at least
a 100 fold greater affinity for the DRR than any other naturally
occurring non-DRR protein), and antibodies made by a process
involving the injection of pharmaceutically acceptable preparations
of such proteins into an animal capable of antibody production. In
a preferred embodiment, monoclonal antibody to human or rat DRR is
produced by injecting a pharmaceutically acceptable preparation of
the receptor into a mouse and then fusing mouse spleen cells with
myeloma cells.
[0007] The invention is also directed to a substantially pure
polynucleotide encoding a protein comprising the amino acid
sequence consisting functionally of the sequence of rat DRR (as
shown in SEQ ID NO:1) or a human DRR (as shown in SEQ ID NOs 3, 5,
7, 9, 11 or 13). This aspect of the invention encompasses
polynucleotides encoding proteins consisting essentially of the
amino acid sequences shown in the sequence listing, expression
vectors comprising such polynucleotides, and host cells transformed
with such vectors. Also included are the recombinant rat and human
DRR proteins produced by host cells made in this manner.
[0008] Preferably, the polynucleotide encoding rat DRR has the
nucleotide sequence shown in SEQ ID NO:2 and the polynucleotide
encoding a human DRR has the nucleotide sequence shown in SEQ ID
NO: 3, 5, 7, 9, 11 or 13. It is also preferred that the vectors and
host cells used for the expression of DRR contain these particular
polynucleotides.
[0009] In another aspect, the present invention is directed to a
method for assaying a test compound for its ability to bind to a
rat or human DRR. The method is performed by incubating a source of
DRR with a ligand known to bind to the receptor and with the test
compound. The source of the DRR should be substantially free of
other types of C; protein-coupled receptors, i.e. greater than 85%
of such receptors present should correspond to the DRR. Upon
completion of incubation, the ability of the test compound to bind
to the DRR is determined by the extent to which ligand binding has
been displaced. The rat DRR should, preferably correspond to rDRR-1
as shown in SEQ ID NO:1. The human receptor should preferably be
hDRR-1 (SEQ ID NO:3); hDRR-2 (SEQ ID NO:5); hDRR-3 (SEQ ID NO:7);
hDRR-4 (SEQ ID NO:9); hDRR-5 (SEQ ID NO:11); or hDRR-6 (SEQ ID
NO:13). Either transformed cells expressing recombinant DR may be
used in the assays or membranes can be prepared from the cells and
used. Although not essential, the assay can be accompanied by the
determination of the activation of a second messenger pathway such
as the adenyl cyclase pathway. This should help to determine
whether a compound that binds to DRR is acting as an agonist or
antagonist.
[0010] An alternative method for determining if a test compound is
an agonist of any of the DRRs disclosed herein is to use a cell
signaling assay, e.g., an assay measuring either intracellular
adenyl cyclase activity or intracellular calcium concentration. The
test compound is incubated with cells expressing the DRR but
substantially free of other G protein-coupled receptors, typically
a cell transfected with an expression vector encoding the DRR. Test
compounds that are agonists are identified by their causing a
statistically significant change in the results obtained from the
cell signaling assay when compared to control transfectants not
exposed to test compound. For example, the cells exposed to the
test compound may show a significant increase in adenyl cyclase
activity or in intracellular calcium concentration.
[0011] The invention also encompasses a method for determining if a
test compound is an antagonist of a DRR which relies upon the known
activation of G protein-coupled receptors that occurs when such
receptors are expressed in large amounts. This method requires that
DNA encoding the receptor be incorporated into an expression vector
so that it is operably linked to a promoter and that the vector
then be used to transfect an appropriate host. In order to produce
sufficient receptor to result in constitutive receptor activation
(i.e., activation in the absence of natural ligand), expression
systems capable of copious protein production are preferred, e.g.,
the DRR DNA may be operably linked to a CMV promoter and expressed
in COS or HEK293 cells. After transfection, cells with activated
receptors are selected based upon their showing increased activity
in a cell signaling assay relative to comparable cells that have
either not been transfected or that have been transfected with a
vector that is incapable of expressing functional DRR. Typically,
cells will be selected either because they show a statistically
significant increase in intracellular adenyl cyclase activity or a
statistically significant increase in intracellular calcium
concentration. The selected cells are contacted with the test
compound and the cell signaling assay is repeated to determine if
this results in a decrease in activity relative to control cells
not contacted with the test compound. For example, a statistically
significant decrease in either adenyl cyclase activity or calcium
concentration relative to control cells would indicate that the
test compound is an antagonist of the DRR. Any of the DRRs
disclosed herein may be used in these assays.
[0012] Assays for compounds interacting with a DRR may be performed
by incubating a source containing the DRR but substantially free of
other G protein-coupled receptors (e.g. a stably transformed cell)
with angiotensin II or III in both the presence and absence of test
compound and measuring the modulation of intracellular calcium
concentration. A significant increase or decrease in
angiotensin-stimulated calcium displacement in response to test
compound is indicative of an interaction occurring at the DRR. The
receptors that may be used in these assays include rat DRR-1 and
human DRR-1, DRR-2, DRR-3, DRR-4, DRR-5 and DRR-6.
[0013] In another aspect, the present invention is directed to a
method for assaying a test compound for its ability to alter the
expression of a rat or human DRR. This method is performed by
growing cells expressing the DRR, but substantially free of other G
protein-coupled receptors, in the presence of the test compound.
Cells are then collected and the expression of the DRR is compared
with expression in control cells grown under essentially identical
conditions but in the absence of the test compound. The rat
receptor is preferably rDRR-1 and the human receptor may be DRR-1;
DRR-2; DRR-3; DRR-4; DRR-5; or DRR-6.
[0014] A preferred test compound is an oligonucleotide at least 15
nucleotides in length comprising a sequence complimentary to the
sequence of the DRR used in the assay.
BRIEF DESCRIPTION OF THE DRAWINGS
[0015] FIG. 1. Nucleotide sequence of rDRR-1: Clone 3B-32, encoding
rDRR-1, was isolated from a rat genomic library using the Promoter
Finder Walking Kit (see Methods, Clontech).
[0016] The cloned gene was deposited with the international
depositary authority Deutsche Sammlung Von Mikroorganismen Und
Zellkulturen GmbH at the address Mascheroder Weg 1 B, D-3300
Braunschweig, Germany. The deposit was made on Nov. 27, 1997 and
was given the accession number DSM 11877.
[0017] FIG. 2. Deduced amino acid sequence of DRR-1: Clone 3B-32
codes for a 337 amino acid protein. The amino acid sequence begins
with the first ATG in the nucleotide sequence.
[0018] FIG. 3. Alignment of the deduced amino acid sequences of
clone 3B-32 (rDRR-1) with its five most homologous sequences. The
boxed and shaded residues are the ones that are identical to the
rDRR-1 sequence.
[0019] FIG. 4. Amino acid alignment of the human DRR homologs: The
amino acid sequence of all 6 human homologs of rDRR-1 (hDRR-1;
hDRR-2; hDRR-3; hDRR-4; hDRR-5; and hDRR-6) are aligned. The amino
acid residues differing from the clone 36 (HUMAN36.PR) are boxed.
The degree of identity among these sequences ranges from 77% to
almost 100%.
DEFINITIONS
[0020] The description that follows uses a number of terms that
refer to recombinant DNA technology. In order to provide a clear
and consistent understanding of the specification and claims,
including the scope to be given such terms, the following
definitions are provided.
Cloning vector: A plasmid or phage DNA or other DNA sequence which
is able to replicate autonomously in a host cell, and which is
characterized by one or a small number of restriction endonuclease
recognition sites A foreign DNA fragment may be spliced into the
vector at these sites in order to bring about the replication and
cloning of the fragment. The vector may contain a marker suitable
for use in the identification of transformed cells. For example,
markers may provide tetracycline resistance or ampicillin
resistance. Expression vector: A vector similar to a cloning vector
but which is capable of inducing the expression of the DNA that has
been cloned into it, after transformation into a host. The cloned
DNA is usually placed under the control of (i.e., operably linked
to) certain regulatory sequences such as promoters or enhancers.
Promoter sequences may be constitutive, inducible or repressible.
Substantially pure: As used herein, "substantially pure" means that
the desired product is essentially free from contaminating cellular
components. A "substantially pure" protein or nucleic acid will
typically comprise at least 85% of a sample, with greater
percentages being preferred. Contaminants may include proteins,
carbohydrates or lipids. One method for determining the purity of a
protein or nucleic acid is by electrophoresing a preparation in a
matrix such as polyacrylamide or agarose. Purity is evidenced by
the appearance of a single band after staining. Other methods for
assessing purity include chromatography and analytical
centrifugation. Host: Any prokaryotic or eukaryotic cell that is
the recipient of a replicable expression vector or cloning vector
is the "host".sup.1 for that vector. The term encompasses
prokaryotic or eukaryotic cells that have been engineered to
incorporate a desired gene on its chromosome or in its genome.
Examples of cells that can serve as hosts are well known in the
art, as are techniques for cellular transformation (see e.g.
Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed.
Cold Spring Harbor (1989)). Promoter: A DNA sequence typically
found in the 5 region of a gene, located proximal to the start
codon. Transcription is initiated at the promoter. If the promoter
is of the inducible type, then the rate of transcription increases
in response to an inducing agent. Complementary Nucleotide
Sequence: A complementary nucleotide sequence, as used herein,
refers to the sequence that would arise by normal base pairing. For
example, the nucleotide sequence 5 AGAC-3 would have the
complementary sequence 5-GTCT-3. Expression: Expression is the
process by which a polypeptide is produced from DNA. The process
involves the transcription of the gene into mRNA and the
translation of this to mRNA into a polypeptide.
DETAILED DESCRIPTION OF THE INVENTION
[0021] The present invention is directed to DRR receptor proteins,
genetic sequences coding for the receptors, a method for assaying
compounds for binding to DRR receptors and a method for assaying
compounds for their ability to alter DRR expression. The receptors
and their nucleic acids are defined by their structures (as shown
in FIGS. 1, 2 and 4; and SEQ ID numbers 1-14).
[0022] It will be understood that the present invention encompasses
not only sequences identical to those shown in the figures and
sequence listing, but also sequences that are essentially the same
and sequences that are otherwise substantially the same and which
result in a receptor retaining the basic binding characteristics of
the DRR. For example, it is well known that techniques such as
site-directed mutagenesis may be used to introduce variations in a
protein's structure. Variations in a DRR protein introduced by this
or some similar method are encompassed by the invention provided
that the resulting receptor retains the basic qualitative binding
characteristics of the unaltered DRR. Thus, the invention relates
to proteins comprising amino acid sequences consisting functionally
of the sequence of SEQ ID NO:1 (rat) and SEQ ID numbers 3, 5, 7, 9,
11 and 14 (human).
I. Nucleic Acid Sequences Coding for DRR
[0023] DNA sequences coding for DRRs are expressed exclusively, or
at least highly preferentially in dorsal root ganglia and these
ganglia may serve as a source for the isolation of nucleic acids
coding for the receptors. In addition, cells and cell lines that
express a rat or human DRR may serve as a source for nucleic acid.
These may either be cultured cells that have not undergone
transformation or cell lines specifically engineered to express
recombinant DRR.
[0024] In all cases, poly A+mRNA is isolated from the dorsal root
ganglia, reverse transcribed to and cloned. The cDNA library thus
formed may then be screened using probes derived from the sequences
shown in the accompanying sequence listing as SEQ D number 2, 4, 6,
8, 10, 12 or 14, depending upon the particular DRR being isolated.
Probes should typically be at least 14 bases in length and should
be derived from a portion of the DRR sequence that is poorly
conserved (see FIGS. 3 and 4). Screening can also be performed
using genomic libraries with one DRR gene, or a portion of the
gene, serving as a probe in the isolation of other DRR genes. For
example, full length rDRR 1 may be labeled and used to screen a
human genomic library for the isolation of hDRR-1, hDRR-2 etc. (see
Examples section).
[0025] Alternatively genomic DNA libraries can be used to isolate
DRR genes by performing PCR amplifications with primers located at
either end of genes (see Examples section for a description of
procedures). For example, human genomic DNA may be amplified using
the primers:
TABLE-US-00001 5'-GCAAGCTTTCTGAGCATGGATCCAACCGTC, and
5'-CCCTCAGATCTCCAATTTGCTTCCCGACAG.
This will serve to amplify all six of the human DRR genes
identified herein as hDRR-1; hDRR-2; hDRR-3; hDRR-4; hDRR-5; and
hDRR-6. These may then be cloned into an appropriate vector, e.g.
pGEM-T (Promega), for DNA sequence analysis.
II. Antibodies to Rat and Human DRRs
[0026] The present invention is also directed to antibodies that
bind specifically to a rat or human DRR and to a process for
producing such antibodies. Antibodies that "bind specifically to a
DRR" are defined as those that have at least a one hundred fold
greater affinity for the DRR than for any other protein. The
process for producing such antibodies may involve to either
injecting the DRR protein itself into an appropriate animal or,
preferably, injecting short peptides made to correspond to
different regions of the DRR. The peptides should be at least five
amino acids in length and should be selected from regions believed
to be unique to the particular DRR protein being targeted. Thus,
highly conserved transmembrane regions should generally be avoided
in selecting peptides for the generation of antibodies. Methods for
making and detecting antibodies are well known to those of skill in
the art as evidenced by standard reference works such as: (Harlow
et al., Antibodies, A Laboratory Manual, Cold Spring Harbor
Laboratory, N.Y. (1988)); Klein, Immunology: The Science of
Self-Nonself Discrimination (1982); Kennett, et al., Monoclonal
Antibodies and Hybridomas: A New Dimension in Biological Analyses
(1980); and Campbell, "Monoclonal Antibody Technology," in
Laboratory Techniques in Biochemistry and Molecular Biology,
(1984)).
[0027] "Antibody" as used herein, is meant to include intact
molecules as well as fragments which retain their ability to bind
to antigen (e.g., Fab and F(ab).sub.2 fragments). These fragments
are typically produced by proteolytically cleaving intact
antibodies using enzymes such as papain (to produce Fab fragments)
or pepsin (to produce F(ab).sub.2 fragments). The term "antibody"
also refers to both monoclonal antibodies and polyclonal
antibodies. Polyclonal antibodies are derived from the sera of
animals immunized with the antigen. Monoclonal antibodies can be
prepared using hybridoma technology (Kohler, et al., Nature 256:495
(1975); Hammerling, et al., in: Monoclonal Antibodies and T-Cell
Hybridomas, Elsevier, M. Y., pp. 563-681 (1981)). In general, this
technology involves immunizing an animal, usually a mouse, with
either intact DRR or a fragment derived from the DRR. The
splenocytes of the immunized animals are extracted and fused with
suitable myeloma cells, e.g., SP2O cells. After fusion, the
resulting hybridoma cells are selectively maintained in HAT medium
and then cloned by limiting dilution (Wands; et al.;
Gastroenterology 80:225-232 (1981)). The cells obtained through
such selection are then assayed to identify clones which secrete
antibodies capable of binding to the DRR.
[0028] The antibodies, or fragments of antibodies, of the present
invention may be used to detect to the presence of DRR protein
using any of a variety of immunoassays. For example, the antibodies
may be used in radioimmunoassays or in immunometric assays, also
known as "two-site" or "sandwich" assays (see Chard, T., "An
Introduction to Radioimmune Assay and Related Techniques," in
Laboratory Techniques in Biochemistry and Molecular Biology, North
Holland Publishing Co., N.Y. (1978)). In a typical immunometric
assay, a quantity of unlabeled antibody is bound to a solid support
that is insoluble in the fluid being tested, e.g., blood, lymph,
cellular extracts, etc. After the initial binding of antigen to
immobilized antibody, a quantity of detectably labeled second
antibody (which may or may not be the same as the first) is added
to permit detection and/or quantitation of bound antigen (see e.g.
Radioimmune Assay Method, Kirkham et al., ed., pp. 199-206, E &
S. Livingstone, Edinburgh (1970)). Many variations of these types
of assays are known in the art and may be employed for the
detection of the DRR.
[0029] Antibodies to a rat or human DRR may also be used in the
purification of either the intact receptor or fragments of the
receptor (see generally, Dean et al., Affinity Chromatography, A
Practical Approach, IRL Press (1986)). Typically, antibody is
immobilized on a chromatographic matrix such as Sepharose 4B. The
matrix is then packed into a column and the preparation containing
the DRR desired is passed through under conditions that promote
binding, e.g., under conditions of low salt. The column is then
washed and bound DRR is eluted using a buffer that promotes
dissociation from antibody, e.g., buffer having an altered pH or
salt concentration. The eluted DRR may be transferred into a buffer
of choice, e.g., by dialysis, and either stored or used
directly.
III. Radioligand Assay for Receptor Binding
[0030] One of the main uses for DRR nucleic acids and recombinant
proteins is in assays designed to identify agents capable of
binding to DRR receptors. Such agents may either be agonists,
mimicking the normal effects of receptor binding, or antagonists,
inhibiting the normal effects of receptor binding. Of particular
interest is the identification of agents which bind to the DRR and
modulate adenyl cyclase activity in the cells. These agents have
potential therapeutic application as either analgesics or
anesthetics.
[0031] In radioligand binding assays, a source of DRR is incubated
together with a ligand known to bind to the receptor and with the
compound being tested for binding activity. The preferred source
for DRR is cells, preferably mammalian cells, transformed to
recombinantly express the receptor. The cells selected should not
express a substantial amount of any other G protein-coupled
receptors that might bind to ligand and distort results. This can
easily be determined by performing binding assays on cells derived
from the same tissue or cell line as those recombinantly expressing
DRR but which have not undergone transformation.
[0032] The assay may be performed either with intact cells or with
membranes prepared from the cells (see e.g. Wang, et al., Proc.
Natl. Acad. Sci. U.S.A. 90:10230-10234 (1993)). The membranes are
incubated with a ligand specific for the DRR receptor and with a
preparation of the compound being tested. After binding is
complete, receptor is separated from the solution containing ligand
and test compound, e.g. by filtration, and the amount of binding
that has occurred is determined. Preferably, the ligand used is
detectably labeled with a radioisotope such as 125I. However, if
desired, fluorescent or chemiluminescent labels can be used
instead. Among the most commonly used fluorescent labeling
compounds are fluorescein isothiocynate, rhodamine, phycoerythrin,
phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
Useful chemiluminescent compounds include luminol, isoluminol,
theromatic acridinium ester, imidazole, acridinium salt, and
oxalate ester. Any of these agents which can be used to produce a
ligand suitable for use in the assay.
[0033] Nonspecific binding may be determined by carrying out the
binding reaction in the presence of a large excess of unlabeled
ligand. For example, labeled ligand may be incubated with receptor
and test compound in the presence of a thousandfold excess of
unlabeled ligand. Nonspecific binding should be subtracted from
total binding, i.e. binding in the absence of unlabeled ligand, to
arrive at the specific binding for each sample tested. Other steps
such as washing, stirring, shaking, filtering and the like may be
included in the assays as necessary. Typically, wash steps are
included after the separation of membrane-bound ligand from ligand
remaining in solution and prior to quantitation of the amount of
ligand bound, e.g., by counting radioactive isotope. The specific
binding obtained in the presence of test compound is compared with
that obtained in the presence of labeled ligand alone to determine
the extent to which the test compound has displaced receptor
binding.
[0034] In performing binding assays, care must be taken to avoid
artifacts which may make it appear that a test compound is
interacting with the DRR receptor when, in fact, binding is being
inhibited by some other mechanism. For example, the compound being
tested should be in a buffer which does not itself substantially
inhibit the binding of ligand to DRR and should, preferably, be
tested at several different concentrations. Preparations of test
compound should also be examined for proteolytic activity and it is
desirable that antiproteases be included in assays. Finally, it is
highly desirable that compounds identified as displacing the
binding of ligand to DRR receptor be reexamined in a concentration
range sufficient to perform a Scatchard analysis on the results.
This type of analysis is well known in the an and can be used for
determining the affinity of a test compounds for receptor (see
e.g., Ausubel, et al., Current Protocols in Molecular Biology,
11.2.1-11.2.19 (1993); Laboratory Techniques and Biochemistry and
Molecular Biology, Work, et al., ed., N.Y. (1978) etc.). Computer
programs may be used to help in the analysis of results (see e.g.,
Munson, P., Methods Enzymol. 92:543-577 (1983); McPherson, G. A.,
Kinetic, EBDA Ligand, Lowry-A Collection of Radioligand Binding
Analysis Programs, Elsevier-Biosoft U. K. (1985)).
[0035] The activation of receptor by the binding of ligand may be
monitored using a number of different assays. For example, adenyl
cyclase assays may be performed by growing cells in wells of a
microliter plate and then incubating the various wells in the
presence or absence of test compound. cAMP may then be extracted in
ethanol, lyophilized and resuspended in assay buffer. Assay of cAMP
thus recovered may be carried out using any method for determining
cAMP concentration, e.g. the Biotrack cAMP Enzyme-immunoassay
System (Amersham) or the Cyclic AMP [3H] Assay System (Amersham).
Typically, adenyl cyclase assays will be performed separately from
binding assays, but it may also be possible to perform binding and
adenyl cyclase assays on a single preparation of cells. Other "cell
signaling assays" that can be used to monitor receptor activity are
described below.
IV. Identification of DRR Agonists and Antagonists Using Cell
Signaling Assays
[0036] DRRs may also be used to screen for drug candidates using
cell signaling assays. To identify DRR agonists, the DNA encoding a
receptor is incorporated into an expression vector and then
transfected into an appropriate host. The transformed cells are
then contacted with a series of test compounds and the effect of
each is monitored. Among the assays that can be used are assays
measuring cAMP production (see discussion above), assays measuring
the activation of reporter gene activity, or assays measuring the
modulation of the binding of GTP-gamma-S.
[0037] Cell signaling assays may also be used to identify DRR
antagonists. G protein-coupled receptors can be put in their active
state even in the absence of their cognate ligand by expressing
them at very high concentration in a heterologous system For
example, receptor may be overexpressed using the baculovirus
infection of insect Sf9 cells or a DRR gene may be operably linked
to a CMV promoter and expressed in COS or HEK293 cells. In this
activated constitutive state, antagonists of the receptor can be
identified in the absence of ligand by measuring the ability of a
test compound to inhibit constitutive cell signaling activity.
Appropriate assays for this are, again, cAMP assays, reporter gene
activation assays or assays measuring the binding of
GTP-gamma-S.
[0038] One preferred cell signaling assay is based upon the
observation that cells stably transfected with DRRs show a change
in intracellular calcium levels in response to incubation in the
presence of angiotensin II or III (see Example 5). Thus, a
procedure can be used to identify DRR agonists or antagonists that
is similar to the radioreceptor assays discussed above except that
angiotensin II or III is used instead of a labeled ligand and to
calcium concentration is measured instead of bound radioactivity.
The concentration of calcium in the presence of test compound and
angiotensin II or III is compared with that in the presence of
angiotensin II or III alone to determine whether the test compound
is interacting at the DRR receptor. A statistically significant
increase in intracellular calcium in response to test compound
indicates that the test compound is acting as an agonist whereas a
statistically significant decrease in intracellular calcium
indicates that it is acting as an antagonist.
V. Assay for Ability to Modulate DRR Expression
[0039] One way to either increase or decrease the biological
effects of a DRR is to alter the extent to which the receptor is
expressed in cells. Therefore, assays for the identification of
compounds that either inhibit or enhance expression are of
considerable interest. These assays are carried out by growing
cells expressing a DRR in the presence of a test compound and then
comparing receptor expression in these cells with expression in
cells grown under essentially identical conditions but in the
absence of the test compound. As in the binding assays discussed
above, it is desirable that the cells used be substantially free of
competing G protein-coupled receptors. One way to quantitate
receptor expression is to fuse the DRR sequence to a sequence
encoding a peptide or protein that can be readily quantitated. For
example, the DRR sequence may be ligated to a sequence encoding
haemaglutinin as described in Example 5 and used to stably
transfect cells. After incubation with test compound the
haemaglutinin/receptor complex can be immunoprecipitated and
western blotted with anti-haemaglutinin antibody. Alternatively,
Scatchard analysis of binding assays may be performed with labeled
ligand to determine receptor number. The binding assays may be
carried out as discussed above and will preferably utilize cells
that have been engineered to recombinantly express DRR.
[0040] A preferred group of test compounds for inclusion in the DRR
expression assay consists of oligonucleotides complementary to
various segments of the DRR nucleic acid sequence. These
oligonucleotides should be at least 15 bases in length and should
be derived from to non-conserved regions of the receptor nucleic
acid sequence. Sequences may be based upon those shown as SEQ ID
numbers 2, 4, 6, 8, 10, 12 or 14.
[0041] Oligonucleotides which are found to reduce receptor
expression may be derivatized or conjugated in order to increase
their effectiveness. For example, nucleoside phosphorothioates may
be substituted for their natural counterparts (see Cohen, J.,
Oligodeoxynucleotides, Antisense Inhibitors of Gene Expression, CRC
Press (1989)). The oligonucleotides may be delivered to a patient
in vivo for the purpose of inhibiting DRR expression. When this is
done, it is preferred that the oligonucleotide be administered in a
form that enhances its uptake by cells. For example, the
oligonucleotide may be delivered by means of a liposome or
conjugated to a peptide that is ingested by cells (see e.g., U.S.
Pat. Nos. 4,897,355 and 4,394,448; see also non-U.S. patent
documents WO 8903849 and EP 0263740). Other methods for enhancing
the efficiency of oligonucleotide delivery are well known in the
art and are also compatible with the present invention.
[0042] Having now described the invention, the same will be more
readily understood through reference to the following Examples
which are provided by way of illustration and which are not
intended to limit the scope of the invention.
EXAMPLES
Example 1
Cloning of Rat DRR-1
[0043] Isolation of cDNA fragment.
[0044] Degenerate oligonucleotides were synthesized to highly
conserved regions of G-protein coupled receptors (transmembrane
spanning domains 2 and 7) with the following nucleotide
sequences:
TABLE-US-00002 5'GG CCG TCG ACT TCA TCG TC(A/T) SEQ ID NO:15
(A/C)(T/C)C TI(G/T) CI(T/C) TIG C(A/C/G/T)G 3' (TM2:sense); and
5'(A/G)(C/AT)(A/T) (A/G)CA (A/G)TA SEQ ID NO:16 IAT IAT IGG (A/G)TT
3' (TM7:antisense).
Poly A+mRNA was isolated from cultured fetal rat dorsal root
ganglia (Sprague-Dawley). The mRNA was reverse transcribed using
the First Strand cDNA Synthesis kit (Pharmacia Biotech), subjected
to an amplification reaction by polymerase chain reaction (PCR)
using Ampli-Taq DNA (Perkin-Elmer Cetus) polymerase under the
following conditions: 3 minutes at 94.degree. C., 40 cycles of 1
minute at 94.degree. C., 45.degree. C. and 72.degree. C. A cDNA PCR
fragment corresponding to approximately 650 bps was isolated and
subcloned in pGEM-T-vector (Promega Corporation). The nucleotide
sequence of the recombinant clone was determined using the
T7-dideoxy chain termination sequencing kit (Pharmacia Biotech) and
was found to be unique based upon searches of Genbank/EMBL
databases.
[0045] The full length rat DRR-1 sequence was obtained from rat
genomic DNA using the 650 base pair fragment and the "Promoter
Finder DNA Walking kit" (Clontech, cat # K1806-1). This kit
contains five libraries of uncloned, adaptor-ligated genomic DNA
fragments. The procedure involves two consecutive PCR reactions.
Both reactions were done using the "Advantage Tth Polymerase Mix"
also obtained from Clontech, following the conditions recommended
by the vendor. The first PCR reaction was performed with the outer
adaptor primer (AP1) provided in the kit and an outer,
gene-specific primer (GSP1) derived from the sequence of the DRR-1
PCR fragment. The primary PCR mixtures were diluted and used as a
template for the secondary (nested) PCR reaction with the nested
adapter primer (AP2) and a nested gene specific primer (GSP2). To
obtain the sequence of the rat DRR-1 gene upstream of the sequence
of the original PCR fragment, the following oligonucleotides were
used:
TABLE-US-00003 GSP1: oligo YF3B59-B, 5'-CGCAGATGAGGTAGTACAGCATCAC
SEQ ID NO:17 GSP2: oligo MML-R1, 5'-CTGTGAGAGAGATGGTAACATACAG SEQ
ID NO:18
[0046] From the first library, a fragment AP2-MMLR1 of 1.9 Kb was
obtained and from the third library, a fragment of approximately
1.0 Kb was obtained. To identify the sequence downstream of the
known sequence, the following primers were used:
TABLE-US-00004 GSP1: oligo YF3B59-F2, 5'-GCATCCTTGACTGGTTCTTCTCAG
SEQ ID NO:19 GSP2: oligo MML-F1, 5'-GGGTGAGACTCATCATCATTTGTGG. SEQ
ID NO:20
[0047] A fragment MMLF1-AP2 of approximately 1 Kb was obtained from
the first library and a fragment of about 600 bp was obtained from
the third library. The composite sequence of 1154 nucleotides
containing the complete predicted open reading frame of DRR-1 is
shown in FIG. 1. The open reading frame codes for a 337 amino acid
protein (FIG. 2) with a predicted molecular mass of 38.7 kD. The
protein sequence contains all the characteristic features of G
protein-coupled receptors: seven hydrophobic helices likely to
represent transmembrane domains, potential glycosylation site at
the N-terminal extracellular domain (position 30) and a conserved
NPXXY sequence at position 285-289.
Example 2
Cloning of Human DRR Receptor Genes
[0048] Two approaches were used to identify and clone novel human
DNA sequences homologous and/or related to the rat DRR-1 gene.
First, a human genomic library was screened in the lambda vector,
Fix II, (Stratagene Cat. #946203). Approximately 106 human genomic
clones were plated and transferred onto nitrocellulose membranes
for hybridization with the full length, 32P labeled, rat DRR-1
sequence as a probe. The hybridization was performed at 42.degree.
C., overnight. The filters were washed at room temperature at low
stringency (1.times.SSC/0.1% SDS) to allow detection of related but
not necessarily identical sequences.
[0049] The inserted human DNA present in positive phages was
amplified by PCR using the "Expand PCR kit" from
Boehringer-Mannheim under conditions allowing accurate
amplification of very large fragments of DNA. These long fragments
of DNA were digested with various restriction enzymes and subcloned
into a plasmid vector. The portions of test clones which hybridized
with the rat DRR-1 gene probe were sequenced using the ABI cycle
sequencing kit.
[0050] A second approach to identifying novel human sequences
related to DRR-1 involved the use of the polymerase chain reaction
(PCR), performed on total human genomic DNA. Primers were
synthesized based upon the human genomic clones described above and
were as follows:
TABLE-US-00005 HML.H, 5'-GCAAGCTTTCTGAGCATGGATCCAACCGTC, SEQ ID 21
and HML.Bg, 5'-CCCTCAGATCTCCAATTTGCTTCCCGACAG,. SEQ ID NO:22
[0051] Amplification resulted in a fragments of approximately 1
kilobase containing the entire coding sequence of the human genes.
These fragments obtained were subcloned into the pGEM-T (Promega)
vector for DNA sequencing analysis.
[0052] Using the above strategies, six human clones were
isolated:
clone 7, SEQ ID numbers 3 and 4; clone 18, SEQ ID numbers 5 and 6;
clone 23, SEQ ID numbers 7 and 8; clone 24, SEQ ID numbers 9 and
10; clone 36, SEQ ID numbers 11 and 12; and clone 40, SEQ ID
numbers 13 and 14.
[0053] None of these clones contain introns and their alignment may
be seen in FIG. 3.
[0054] At the amino acid sequence level, the rat DRR-1 clone is 47%
to 49% identical to the human clones.
[0055] At the nucleic acid level, the rat DRR-1 clone is 56% to 58%
identical to the human clones. The level of sequence identity
within the human clones (7, 18, 23, 24, 36, 40) is very high,
between 77% and 98% at the amino acid sequence level. All the human
sequences were used as queries to search for homologies in public
databases (Genbank, Swissprot, EST. No identical sequences were
detected. The closest matches were to members of the mas oncogene
family of proteins. The overall amino acid sequence homology
between rat DRR-1 and any of the isolated human genes varied from
47 to 50%. However some stretches display a much higher level of
sequence homology, particularly the regions encoding the putative
transmembrane domain III and VII (TM3 and TM7) and the
intracellular loops 2 and 3 where the homology between the rat
sequence and its human homologue is around 80%.
Example 3
In Situ Hybridization Experiments
[0056] Preparation of Tissue: Adult male Sprague-Dawley rats
(.about.300 gm; Charles River, St-Constant, Quebec) were sacrificed
by decapitation. Brain and spinal cord with dorsal root ganglia
attached were removed, snap-frozen in isopentane at 40.degree. C.
for 20 s and stored at -80.degree. C. Frozen human brain, spinal
cord and dorsal root ganglia were obtained from the Brain and
Tissue Bank for Developmental Disorders, University of Maryland at
Baltimore, according to the strictest ethical guidelines. Frozen
tissue was sectioned at 14 m in a Microm HM 500 M cryostat
(Germany) and thaw-mounted onto ProbeOn Plus slides (Fisher
Scientific, Montreal, Quebec). Sections were stored at -80.degree.
C. prior to in situ hybridization.
[0057] Synthesis of Riboprobes: The plasmid pGemT-3b32 GPCR was
linearized using either SacII and Not 1 restriction enzymes. Sense
and antisense DRR riboprobes were transcribed in vitro using either
T7 or SP6 RNA polymerases (Pharmacia Biotech), respectively in the
presence of [35S]UTP (.about.800 Ci/mmol; Amersham, Oakville,
Ontario). The plasmid pGemT-Clone 36 GPCR was linearized using
SacII and Pst 1 restriction enzymes. Sense and antisense Clon36
riboprobes were transcribed in vitro using either SP6 or 17 RNA
polymerases (Pharmacia Biotech), respectively in the presence of
[35S]UTP. Following transcription, the DNA template was digested
with DNAse I (Pharmacia). Riboprobes were purified by
phenol/chloroform/isoamyl alcohol extraction and precipitated in
70% ethanol containing ammonium acetate and tRNA. Quality of
labeled riboprobes was verified by polyacrylamide-urea gel
electrophoresis.
[0058] In situ Hybridization: Sections were postfixed in 4%
paraformaldehyde (BDH, Poole, England) in 0.1 M phosphate buffer
(pH 7.4) for 10 min at room temperature (RT) and rinsed in three
changes of 2.times. standard sodium citrate buffer (SSC; 0.15 M
NaCl. 0.015 M sodium citrate, pH 7.0). Sections were then
equilibrated in 0.1 M triethanolamine, treated with 0.25% acetic
anhydride in triethanolamine, rinsed in 2.times.SSC and dehydrated
in an ethanol series (50-100%). Hybridization was performed in a
buffer containing 75% formamide (Sigma, St-Louis, Mo.), 600 mM
NaCl, 10 mM Tris (pH 7.5), 1 mM EDTA, 1.times.Denhardt's solution
(Sigma), 50 (g/ml denatured salmon sperm DNA (Sigma), 50 (g/ml
yeast tRNA (Sigma), 10% dextran sulfate (Sigma), 20 mM
dithiothreitol and [35S]UTP-labeled cRNA probes (10.times.106
cpm/ml) at 55.degree. C. for 18 h in humidified chambers. Following
hybridization, slides were rinsed in 2.times.SSC at RT, treated
with 20 (g/ml RNase IA (Pharmacia) in RNase buffer (10 mM Tris, 500
mM NaCl, 1 mM EDTA, pH 7.5) for 45 min at RT and washed to a final
stringency of 0.1.times.SSC at 65.degree. C. Sections were then
dehydrated and exposed to Kodak Biomax MR film for 21 days and/or
dipped in Kodak NTB2 emulsion diluted 1:1 with distilled water and
exposed for 4-6 weeks at 4.degree. C. prior to development and
counterstaining with cresyl violet acetate (Sigma).
[0059] Results: Of all regions examined within the neuraxis of the
rat, DRR-1 mRNA was exclusively expressed in dorsal root ganglia.
High resolution emulsion autoradiography showed accumulations of
silver grains exclusively over small and some medium size neurons.
This unique and highly restricted distribution pattern for DRR-1
was confirmed in to the rat embryo. Sagittal section of an E17 rat
fetus showed that DRR-1 mRNA is confined to DRGs. All other
structures of the rat embryo were devoid of any specific
hybridization signal reinforcing the highly selective nature of
DRR-1 expression
[0060] The expression of human Clone 36 receptor was present in
human fetal dorsal root ganglia but not in spinal cord. Specific
hybridization signal for Clone 36 was not detected in any of the
human adult CNS tissues examined thus far. These include spinal
cord, cortex, hippocampus, thalamus, substantia nigra and
periaqueductal gray (data not shown). Presence of Clone 36 mRNA in
adult DRGs remains to be examined. Standard controls in which
additional spinal cord with DRG sections were hybridized with rat
DRR-1 antisense or Clone 36 sense 35S-labeled probes displayed no
specific hybridization signal.
Example 4
Northern Blots
[0061] Commercial rat and human multiple Northern blots containing
2 g of polyA RNA from various tissues (Clontech) were used to
determine the expression and distribution of the rat DRR-1 message
and its human homologues. Radioactively labeled probes were
prepared as follows: twenty five ng of a 650 bp 3b-32 PCR fragment
derived from rat DRR-1 (see Example 1) or human clone 36 were
random-prime labeled using the Ready-to-Go DNA labeling kit
(Pharmacia Biotech) and [32P]CTP (3000 Ci/mmol/Amersham). The blot
was prehybridized for 1 hour at 68.degree. C. using Expresshyb
(Clontech) followed by hybridization (2.times.106 cpm/ml of probe)
for one hour using the same conditions. Blots were washed at room
temperature in 2.times.SSC, 0.05% SDS for 30 min. followed by
3.times. washes in 0.2.times.SSC, 1% SDS at 50.degree. C. for 60
min. and exposed at -80.degree. C. to Kodak Biomax film for 6
days.
[0062] Expression and Distribution of rat DRR-1: All the rat
tissues studied (heart, brain, spleen, lung, skeletal muscle,
kidney and testis) were negative for the expression of DRR-1
following 2 weeks exposure whereas rat genomic Southern analysis
revealed a 1.1 kb band when probed with the same cDNA fragment.
[0063] Expression and Distribution of Human Clone 36: Northern
blots containing RNA from various human tissues were probed with a
radio-labeled DNA fragment from clone 36. All the human tissues
studied (human fetal brain, lung, liver and kidney and adult human
cerebellum, cerebral cortex, medulla, occipital pole, frontal lobe,
temporal lobe, putamen, spinal cord, amygdala, caudate nucleus,
corpus callosum, hippocampus, total brain, subthalamic nucleus and
thalamus) were negative for the expression of this receptor
following 2 weeks exposure.
Example 5
Calcium Signaling in Response to Angiotensin I-III
[0064] The coding sequence of human clone 24 was transferred into a
pcDNA3 vector and modified to add a haemaglutinin tag at the
C-terminus of the receptor sequence. This clone, designated as
pcDNA3-HML-HA24 was transfected into HEK293 cells using a modified
CaCl.sub.2 method (Maniatis, Molecular Cloning: A Laboratory
Manual, Cold Spring Harbor Laboratory Press (1989)). The cells were
maintained in culture medium at 37.degree. C., 5% CO.sub.2 and
diluted 10 fold every 3 days.
[0065] The cells were inoculated in 90 mm tissue culture dishes
(5.times.105 cells per flask) in Dulbecco's Modified Essential
Medium (DMEM, Gibco BRL), supplemented with 10% fetal bovine serum
(FBS), 100 U/ml penicillin, 100 .mu.g/ml streptomycin and 0.25
.mu.g/ml fungizone. One day after inoculation, cells were
transiently transfected with 30 .mu.g of plasmid DNA per dish. The
cells were harvested 48 hours post transfection for analysis.
[0066] The expression of the gene was first checked by
immunoprecipitation and western blotting with an anti-haemaglutinin
antibody. A protein of approximately 43 KD was detected in stably
as well as transiently transfected HEK293 cells, but not in control
cells.
[0067] Stably transfected HEK293 cells were obtained after
approximately 21 days of selection in culture medium containing 800
.mu.g/ml G418. Calcium signaling measurement was performed with one
of these stably transfected cell line, 293/pcDNA3-HML-HA24. The
cells were grown on a 24 mm round glass cover slides to 50-70%
confluence. After rinsing the cells with 1.8 NBS buffer (135 mM
NaCl, 5 mM KCl, 1.2 mM MgCl.sub.2, 1.8 mM CaCl.sub.2, 5 mM glucose
and 10 mM HEPES, pH 7.3), the cells were incubated for one hour at
room temperature in the presence of 0.5 ml of 3.5 .mu.M FURA-2 AM
(Molecular Probe, F-1221) diluted in 1.8 NBS. The cells were then
rinsed three times with 1.8 NBS and incubated for a further 30
minutes at room temperature. The calcium displacement was measured
using a PTI (Photon Technology International) D104 photometer
equipped with a PTI Delta RAM High speed multiwavelength
illuminator, a PTI SC500 Shutter controller, a PTI LPS220 ARC lamp
supply and the PTI FELIX software, v.1.2. Groups of 2 to 8 cells
were chosen and isolated with the photometer diaphragm. The cells
were exposed to 340 and 380 nm light and the 510 nm light emitted
by the cells was recorded. Angiotensin I, II and III, were added
successively--in various order from one experiment to the
next--followed by bradykinin as a positive control. Upon
stimulation with angiotensin II and angiotensin III, a significant
response was obtained. Addition of angiotensin I produced no
response.
[0068] All references cited herein are fully incorporated by
reference, Having now fully described the invention, it will be
understood by one of skill in the art that the invention may be
performed within a wide and equivalent range of conditions,
parameters and the like, without affecting the spirit or scope of
the invention or any embodiment thereof.
Sequence CWU 1
1
221337PRTrat 1Met Val Cys Val Leu Arg Asp Thr Thr Gly Arg Phe Val
Ser Met Asp1 5 10 15Pro Thr Ile Ser Ser Leu Ser Thr Glu Ser Thr Thr
Leu Asn Lys Thr 20 25 30Gly His Pro Ser Cys Arg Pro Ile Leu Thr Leu
Ser Phe Leu Val Pro 35 40 45Ile Ile Thr Leu Leu Gly Leu Ala Gly Asn
Thr Ile Val Leu Trp Leu 50 55 60Leu Gly Phe Arg Met Arg Arg Lys Ala
Ile Ser Val Tyr Val Leu Asn65 70 75 80Leu Ser Leu Ala Asp Ser Phe
Phe Leu Cys Cys His Phe Ile Asp Ser 85 90 95Leu Met Arg Ile Met Asn
Phe Tyr Gly Ile Tyr Ala His Lys Leu Ser 100 105 110Lys Glu Ile Leu
Gly Asn Val Ala Phe Ile Pro Tyr Ile Ser Gly Leu 115 120 125Ser Ile
Leu Ser Ala Ile Ser Thr Glu Arg Cys Leu Ser Val Leu Trp 130 135
140Pro Ile Trp Tyr His Cys His Arg Pro Arg Asn Met Ser Ala Ile
Ile145 150 155 160Cys Val Leu Ile Trp Val Leu Ser Phe Leu Met Gly
Ile Leu Asp Trp 165 170 175Phe Phe Ser Gly Phe Leu Gly Glu Thr His
His His Leu Trp Lys Asn 180 185 190Val Asp Phe Ile Val Thr Ala Phe
Leu Ile Phe Leu Phe Met Leu Leu 195 200 205Phe Gly Ser Ser Leu Ala
Leu Leu Val Arg Ile Leu Cys Gly Ser Arg 210 215 220Arg Lys Pro Leu
Ser Arg Leu Tyr Val Thr Ile Ser Leu Thr Val Met225 230 235 240Val
Tyr Leu Ile Cys Gly Leu Pro Leu Gly Leu Tyr Leu Phe Leu Leu 245 250
255Tyr Trp Phe Gly Ile His Leu His Tyr Pro Phe Cys His Ile Tyr Gln
260 265 270Val Thr Val Leu Leu Ser Cys Val Asn Ser Ser Ala Asn Pro
Ile Ile 275 280 285Tyr Phe Leu Val Gly Ser Phe Arg His Arg Lys Lys
His Arg Ser Leu 290 295 300Lys Met Val Leu Lys Arg Ala Leu Glu Glu
Thr Pro Glu Glu Asp Glu305 310 315 320Tyr Thr Asp Ser His Val Gln
Lys Pro Thr Glu Ile Ser Glu Arg Arg 325 330 335Cys21011DNArat
2atggtttgtg ttctcaggga cactactgga agatttgtga gcatggatcc aaccatctca
60tccctcagta cagaatctac aacactgaat aaaactggtc atcccagttg caggccaatc
120ctcaccctgt ccttcctggt ccccatcatc accctgcttg gattggcagg
aaacaccatt 180gtactctggc tcttgggatt ccgcatgcgc aggaaagcca
tctcagtcta cgtcctcaac 240ctgtctctgg cagactcctt cttcctctgc
tgccatttta ttgactctct gatgcggatc 300atgaacttct atggcatcta
tgcccataaa ttaagcaaag aaatcttagg caatgtagca 360ttcattccct
atatctcagg cctgagcatc ctcagtgcta tcagcacgga gcgctgcctg
420tctgtattgt ggccaatctg gtaccactgc caccgcccaa gaaacatgtc
agctattata 480tgtgttctaa tctgggttct gtcctttctc atgggcatcc
ttgactggtt tttctcagga 540ttcctgggtg agactcacca tcatttgtgg
aaaaatgttg actttattgt aactgcattt 600ctgatttttt tatttatgct
tctctttggg tccagtctgg cgctactggt gaggatcctc 660tgtggttcca
gacggaaacc actgtccagg ctgtacgtta caatctctct cacagtgatg
720gtctacctca tctgcggcct gcctctcggg ctttacttgt tcctgctata
ttggtttggg 780atccatttac attatccctt ttgtcacatt taccaagtta
ctgtgctcct gtcctgtgtg 840aacagctctg ccaaccccat catttacttc
cttgtagggt cctttaggca ccgtaaaaag 900catcggtccc tcaaaatggt
tcttaaaagg gctctggagg agactcctga ggaggatgaa 960tatacagaca
gccatgttca gaaacccact gagatctcag aaaggagatg t 10113322PRTHomo
sapiens 3Met Asp Pro Thr Ile Pro Val Leu Gly Thr Lys Leu Thr Pro
Ile Asn1 5 10 15Gly Arg Glu Glu Thr Pro Cys Tyr Asn Gln Thr Leu Ser
Phe Thr Gly 20 25 30Leu Thr Cys Ile Ile Ser Leu Val Ala Leu Thr Gly
Asn Ala Val Val 35 40 45Leu Trp Leu Leu Gly Cys Arg Met Arg Arg Asn
Ala Val Ser Ile Tyr 50 55 60Ile Leu Asn Leu Val Ala Ala Asn Phe Leu
Phe Leu Ser Gly His Ile65 70 75 80Ile Phe Ser Pro Leu Pro Leu Ile
Asn Ile Arg His Pro Ile Ser Lys 85 90 95Ile Leu Ser Pro Val Met Thr
Phe Pro Tyr Phe Ile Gly Leu Ser Met 100 105 110Leu Ser Ala Ile Ser
Thr Glu Arg Cys Leu Ser Ile Leu Trp Pro Ile 115 120 125Trp Tyr His
Cys Arg Arg Pro Arg Tyr Leu Ser Ser Val Met Cys Val 130 135 140Leu
Leu Trp Ala Leu Ser Leu Leu Arg Ser Ile Leu Glu Trp Met Phe145 150
155 160Cys Asp Phe Leu Phe Ser Gly Ala Asn Ser Val Trp Cys Glu Thr
Ser 165 170 175Asp Phe Ile Thr Ile Ala Trp Leu Val Phe Leu Cys Val
Val Leu Cys 180 185 190Gly Ser Ser Leu Val Leu Leu Val Arg Ile Leu
Cys Gly Ser Arg Lys 195 200 205Met Pro Leu Thr Arg Leu Tyr Val Thr
Ile Leu Leu Thr Val Leu Val 210 215 220Phe Leu Leu Cys Gly Leu Pro
Phe Gly Ile Gln Trp Ala Leu Phe Ser225 230 235 240Arg Ile His Leu
Asp Trp Lys Val Leu Phe Cys His Val His Leu Val 245 250 255Ser Ile
Phe Leu Ser Ala Leu Asn Ser Ser Ala Asn Pro Ile Ile Tyr 260 265
270Phe Phe Val Gly Ser Phe Arg Gln Arg Gln Asn Arg Gln Asn Leu Lys
275 280 285Leu Val Leu Gln Arg Ala Leu Gln Asp Thr Pro Glu Val Asp
Glu Gly 290 295 300Gly Gly Trp Leu Pro Gln Glu Thr Leu Glu Leu Ser
Gly Ser Lys Leu305 310 315 320Glu Gln4969DNAHomo sapiens
4atggatccaa ccatcccagt cttgggtaca aaactgacac caatcaacgg acgtgaggag
60actccttgct acaaccaaac cctgagcttc acggggctga cgtgcatcat ttcccttgtc
120gcgctgacag gaaacgcggt tgtgctctgg ctcctgggct gccgcatgcg
caggaacgct 180gtctccatct acatcctcaa cctggtcgcg gccaacttcc
tcttccttag cggccacatt 240atattttcgc cgttacccct catcaatatc
cgccatccca tctccaaaat cctcagtcct 300gtgatgacct ttccctactt
tataggccta agcatgctga gcgccatcag caccgagcgc 360tgcctgtcca
tcctgtggcc catctggtac cactgccgcc gccccagata cctgtcatcg
420gtcatgtgtg tcctgctctg ggccctgtcc ctgctgcgga gtatcctgga
gtggatgttc 480tgtgacttcc tgtttagtgg tgctaattct gtttggtgtg
aaacgtcaga tttcattaca 540atcgcgtggc tggttttttt atgtgtggtt
ctctgtgggt ccagcctggt cctgctggtc 600aggattctct gtggatcccg
gaagatgccg ctgaccaggc tgtacgtgac catcctcctc 660acagtgctgg
tcttcctcct ctgtggcctg ccctttggca ttcagtgggc cctgttttcc
720aggatccacc tggattggaa agtcttattt tgtcatgtgc atctagtttc
cattttcctg 780tccgctctta acagcagtgc caaccccatc atttacttct
tcgtgggctc ctttaggcag 840cgtcaaaata ggcaaaacct gaagctggtt
ctccaaaggg ctctgcagga cacgcctgag 900gtggatgaag gtggagggtg
gcttcctcag gaaaccctgg agctgtcggg aagcaaattg 960gagcagtga
9695322PRTHomo sapiens 5Met Asp Pro Thr Val Pro Val Leu Gly Thr Glu
Leu Thr Pro Ile Asn1 5 10 15Gly Arg Glu Glu Thr Pro Cys Tyr Lys Gln
Thr Leu Ser Phe Thr Gly 20 25 30Leu Thr Cys Ile Val Ser Leu Val Ala
Leu Thr Gly Asn Ala Val Val 35 40 45Leu Trp Leu Leu Gly Cys Arg Met
Arg Arg Asn Ala Val Ser Ile Tyr 50 55 60Ile Leu Asn Leu Val Ala Ala
Asp Phe Leu Phe Leu Ser Gly His Ile65 70 75 80Ile Cys Ser Pro Leu
Arg Leu Ile Asn Ile Ser His Pro Ile Ser Lys 85 90 95Ile Leu Ser Pro
Val Met Thr Phe Pro Tyr Phe Ile Gly Leu Ser Met 100 105 110Leu Asn
Ala Ile Ser Thr Glu Arg Cys Leu Ser Ile Leu Trp Pro Ile 115 120
125Trp Tyr His Cys Arg Arg Pro Arg Tyr Leu Ser Ser Val Met Cys Val
130 135 140Leu Leu Trp Ala Pro Ser Leu Leu Arg Ser Ile Leu Glu Trp
Met Phe145 150 155 160Cys Asp Phe Leu Phe Ser Gly Ala Asp Ser Val
Arg Cys Glu Thr Ser 165 170 175Asp Phe Ile Thr Ile Ala Trp Leu Val
Phe Leu Arg Val Val Leu Cys 180 185 190Gly Ser Ser Leu Val Leu Leu
Val Arg Ile Leu Cys Gly Ser Arg Lys 195 200 205Met Pro Leu Thr Arg
Leu Tyr Val Thr Ile Leu Leu Thr Val Leu Val 210 215 220Phe Leu Leu
Cys Gly Leu Pro Phe Gly Ile Gln Trp Ala Leu Phe Ser225 230 235
240Arg Ile His Leu Asp Trp Lys Val Leu Phe Cys His Val His Leu Val
245 250 255Ser Ile Phe Leu Ser Ala Leu Asn Ser Ser Ala Asn Pro Ile
Ile Tyr 260 265 270Phe Phe Met Gly Ser Phe Arg Gln Leu Gln Asn Arg
Lys Thr Leu Lys 275 280 285Leu Val Leu Gln Arg Asp Leu Gln Asp Thr
Pro Glu Val Asp Glu Gly 290 295 300Gly Trp Trp Leu Pro Gln Glu Thr
Leu Glu Leu Ser Gly Ser Lys Leu305 310 315 320Glu Ile6969DNAHomo
sapiens 6atggatccaa ccgtcccagt cttgggtaca gaactgacac caatcaacgg
acgtgaggag 60actccttgct acaagcagac cctgagcttc acggggctga cgtgcatcgt
ttcccttgtc 120gcgctgacag gaaacgcggt tgtgctctgg ctcctgggct
gccgcatgcg caggaacgct 180gtctccatct acatcctcaa cctggtcgcg
gccgacttcc tcttccttag cggccacatt 240atatgttcgc cgttacgcct
catcaatatc agccatccca tctccaaaat cctcagtcct 300gtgatgacct
ttccctactt tataggccta agcatgctga acgccatcag caccgagcgc
360tgcctgtcca tcctgtggcc catctggtac cactgccgcc gccccagata
cctgtcatcg 420gtcatgtgtg tcctgctctg ggccccgtcc ctgctgcgga
gtatcctgga gtggatgttc 480tgtgacttcc tgtttagtgg tgctgattct
gttcggtgtg aaacgtcaga tttcattaca 540atcgcgtggc tggttttttt
acgtgtggtt ctctgtgggt ccagcctggt cctgctggtc 600aggattctct
gtggatcccg gaagatgccg ctgaccaggc tgtacgtgac catcctcctc
660acagtgctgg tcttcctcct ctgtggcctg ccctttggca ttcagtgggc
cctgttttcc 720aggatccacc tggattggaa agtcttattt tgtcatgtgc
atctagtttc cattttcctg 780tccgctctta acagcagtgc caaccccatc
atttacttct tcatgggctc ctttaggcag 840cttcaaaaca ggaagaccct
caagctggtt ctccagaggg atctgcagga cacgcctgag 900gtggatgaag
gtggatggtg gcttcctcag gaaaccctgg agctgtcggg aagcaaattg 960gagatctga
9697322PRTHomo sapiens 7Met Asp Pro Thr Val Ser Thr Leu Asp Thr Glu
Leu Thr Pro Ile Asn1 5 10 15Gly Thr Glu Glu Thr Leu Cys Tyr Lys Gln
Thr Leu Ser Leu Thr Val 20 25 30Leu Thr Cys Ile Val Ser Leu Val Gly
Leu Thr Gly Asn Ala Val Val 35 40 45Leu Trp Leu Leu Gly Cys Arg Met
Arg Arg Asn Ala Phe Ser Ile Tyr 50 55 60Ile Leu Asn Leu Ala Ala Ala
Asp Phe Leu Phe Leu Ser Gly Arg Leu65 70 75 80Ile Tyr Ser Leu Leu
Ser Phe Ile Ser Ile Pro His Thr Ile Ser Lys 85 90 95Ile Leu Tyr Pro
Val Met Met Phe Ser Tyr Phe Ala Gly Leu Asn Phe 100 105 110Leu Ser
Ala Val Ser Thr Asp Arg Cys Leu Ser Val Leu Trp Pro Ile 115 120
125Trp Tyr Arg Cys His Arg Pro Thr His Leu Ser Ala Val Val Cys Val
130 135 140Leu Leu Trp Ala Leu Ser Leu Leu Arg Ser Ile Leu Glu Trp
Met Leu145 150 155 160Cys Gly Phe Leu Phe Ser Gly Ala Asp Ser Ala
Trp Cys Gln Thr Ser 165 170 175Asp Phe Ile Thr Val Ala Trp Leu Ile
Phe Leu Cys Val Val Leu Cys 180 185 190Gly Ser Ser Leu Val Leu Leu
Ile Arg Ile Leu Cys Gly Ser Arg Lys 195 200 205Ile Pro Leu Thr Arg
Leu Tyr Val Thr Ile Leu Leu Thr Val Leu Val 210 215 220Phe Leu Leu
Cys Gly Leu Pro Phe Gly Ile Gln Phe Phe Leu Phe Leu225 230 235
240Trp Ile His Val Asp Arg Glu Val Leu Phe Cys His Val His Leu Val
245 250 255Ser Ile Phe Leu Ser Ala Leu Asn Ser Ser Ala Asn Pro Ile
Ile Tyr 260 265 270Phe Phe Val Gly Ser Leu Arg Gln Arg Gln Asn Arg
Gln Asn Leu Lys 275 280 285Leu Val Leu Gln Arg Ala Leu Gln Asp Thr
Pro Glu Val Asp Glu Gly 290 295 300Gly Gly Trp Leu Pro Gln Glu Thr
Leu Glu Leu Ser Gly Ser Arg Leu305 310 315 320Glu Gln8969DNAHomo
sapiens 8atggatccaa ccgtctcaac cttggacaca gaactgacac caatcaacgg
aactgaggag 60actctttgct acaagcagac cttgagcctc acggtgctga cgtgcatcgt
ttcccttgtc 120gggctgacag gaaacgcagt tgtactctgg ctcctgggct
gccgcatgcg caggaacgcc 180ttctccatct acatcctcaa cttggccgca
gcagacttcc tcttcctcag cggccgcctt 240atatattccc tgttaagctt
catcagtatc ccccatacca tctctaaaat cctctatcct 300gtgatgatgt
tttcctactt tgcaggcctg aactttctga gtgccgtgag caccgatcgc
360tgcctgtccg tcctgtggcc catctggtac cgctgccacc gccccacaca
cctgtcagcg 420gtggtgtgtg tcctgctctg ggccctgtcc ctgctgcgga
gcatcctgga atggatgtta 480tgtggcttcc tgttcagtgg tgctgattct
gcttggtgtc aaacatcaga tttcatcaca 540gtcgcgtggc tgattttttt
atgtgtggtt ctctgtgggt ccagcctggt cctgctgatc 600aggattctct
gtggatcccg gaagataccg ctgaccaggc tgtacgtgac catcctgctc
660acagtactgg tcttcctcct ctgtggcctg ccctttggca ttcagttttt
cctattttta 720tggatccacg tggacaggga agtcttattt tgtcatgtgc
atctagtttc cattttcctg 780tccgctctta acagcagtgc caaccccatc
atttacttct tcgtgggctc ccttaggcag 840cgtcaaaata ggcagaacct
gaagctggtt ctccagaggg ctctgcagga cacgcctgag 900gtggatgaag
gtggagggtg gcttcctcag gaaaccctgg agctgtcggg aagcagattg 960gagcagtga
9699322PRTHomo sapiens 9Met Asp Pro Thr Val Ser Thr Leu Asp Thr Glu
Leu Thr Pro Ile Asn1 5 10 15Gly Thr Glu Glu Thr Leu Cys Tyr Lys Gln
Thr Leu Ser Leu Thr Val 20 25 30Leu Thr Cys Ile Val Ser Leu Val Gly
Leu Thr Gly Asn Ala Val Val 35 40 45Leu Trp Leu Leu Gly Cys Arg Met
Arg Arg Asn Ala Phe Ser Ile Tyr 50 55 60Ile Leu Asn Leu Ala Ala Ala
Asp Phe Leu Phe Leu Ser Gly Arg Leu65 70 75 80Ile Tyr Ser Leu Leu
Ser Phe Ile Ser Ile Pro His Thr Ile Ser Lys 85 90 95Ile Leu Tyr Pro
Val Met Met Phe Ser Tyr Phe Ala Gly Leu Ser Phe 100 105 110Leu Ser
Ala Val Ser Thr Glu Arg Cys Leu Ser Val Leu Trp Pro Ile 115 120
125Trp Tyr Arg Cys His Arg Pro Thr His Leu Ser Ala Val Val Cys Val
130 135 140Leu Leu Trp Ala Leu Ser Leu Leu Arg Ser Ile Leu Glu Trp
Met Leu145 150 155 160Cys Gly Phe Leu Phe Ser Gly Ala Asp Ser Ala
Trp Cys Gln Thr Ser 165 170 175Asp Phe Ile Thr Val Ala Trp Leu Ile
Phe Leu Cys Val Val Leu Cys 180 185 190Gly Ser Ser Leu Val Leu Leu
Ile Arg Ile Leu Cys Gly Ser Arg Lys 195 200 205Ile Pro Leu Thr Arg
Leu Tyr Val Thr Ile Leu Leu Thr Val Leu Val 210 215 220Phe Leu Leu
Cys Gly Leu Pro Phe Gly Ile Gln Phe Phe Leu Phe Leu225 230 235
240Trp Ile His Val Asp Arg Glu Val Leu Phe Cys His Val His Leu Val
245 250 255Ser Ile Phe Leu Ser Ala Leu Asn Ser Ser Ala Asn Pro Ile
Ile Tyr 260 265 270Phe Phe Val Gly Ser Phe Arg Gln Arg Gln Asn Arg
Gln Asn Leu Lys 275 280 285Leu Val Leu Gln Arg Ala Leu Gln Asp Ala
Ser Glu Val Asp Glu Gly 290 295 300Gly Gly Gln Leu Pro Gln Glu Thr
Leu Glu Leu Ser Gly Ser Arg Leu305 310 315 320Glu Gln10969DNAHomo
sapiens 10atggatccaa cggtctcaac cttggacaca gaattgacac caatcaacgg
aactgaggag 60actctttgct acaagcagac cttgagcctc acggtgctga cgtgcatcgt
ttcccttgtc 120gggctgacag gaaacgcggt tgtgctctgg ctcctgggct
gccgcatgcg caggaacgcc 180ttctccatct acatcctcaa cttggccgca
gcagacttcc tcttcctcag cggccgcctt 240atatattccc tgttaagctt
catcagtatc ccccatacca tctctaaaat cctctatcct 300gtgatgatgt
tttcctactt tgcaggcctg agctttctga gtgccgtgag caccgagcgc
360tgcctgtccg tcctgtggcc catctggtac cgctgccacc gccccacaca
cctgtcagcg 420gtggtgtgtg tcctgctctg ggccctgtcc ctgctgcgga
gcatcctgga gtggatgtta 480tgtggcttcc tgttcagtgg tgctgattct
gcttggtgtc aaacatcaga tttcatcaca 540gtcgcgtggc tgattttttt
atgtgtggtt ctctgtgggt ccagcctggt cctgctgatc 600aggattctct
gtggatcccg gaagataccg ctgaccaggc tgtacgtgac catcctgctc
660acagtactgg tcttcctcct ctgtggcctg ccctttggca ttcagttttt
cctattttta 720tggatccacg tggacaggga agtcttattt tgtcatgttc
atctagtttc tattttcctg 780tccgctctta acagcagtgc caaccccatc
atttacttct tcgtgggctc ctttaggcag 840cgtcaaaata ggcagaacct
gaagctggtt ctccagaggg ctctgcagga cgcgtctgag 900gtggatgaag
gtggagggca gcttcctgag gaaatcctgg agctgtcggg aagcagattg
960gagcagtga
96911322PRTHomo sapiens 11Met Asp Pro Thr Val Pro Val Leu Gly Thr
Lys Leu Thr Pro Ile Asn1 5 10 15Gly Arg Glu Glu Thr Pro Cys Tyr Lys
Gln Thr Leu Ser Phe Thr Val 20 25 30Leu Thr Cys Ile Ile Ser Leu Val
Gly Leu Thr Gly Asn Ala Val Val 35 40 45Leu Trp Leu Leu Gly Cys Arg
Met Arg Arg Asn Ala Val Ser Ile Tyr 50 55 60Ile Leu Asn Leu Ala Ala
Ala Asp Phe Leu Phe Leu Ser Phe Gln Ile65 70 75 80Ile Cys Arg Pro
Leu Arg Leu Ile Asn Ile Ser His Leu Ile Arg Lys 85 90 95Ile Leu Val
Ser Val Met Thr Phe Pro Tyr Phe Thr Gly Leu Ser Met 100 105 110Leu
Ser Ala Ile Ser Thr Glu Arg Cys Leu Ser Val Leu Trp Pro Ile 115 120
125Trp Tyr Arg Cys Arg Arg Pro Thr His Leu Ser Ala Val Val Cys Val
130 135 140Leu Leu Trp Ala Gly Leu Leu Leu Phe Ser Met Leu Glu Trp
Arg Phe145 150 155 160Cys Asp Phe Leu Phe Ser Gly Ala Asp Ser Ser
Trp Cys Glu Thr Ser 165 170 175Asp Phe Ile Pro Val Ala Trp Leu Ile
Phe Leu Cys Val Val Leu Cys 180 185 190Val Ser Ser Leu Val Leu Leu
Val Arg Ile Leu Cys Gly Ser Arg Lys 195 200 205Met Pro Leu Thr Arg
Leu Tyr Val Thr Ile Leu Leu Thr Val Leu Val 210 215 220Phe Leu Leu
Cys Gly Leu Pro Phe Gly Ile Leu Gly Ala Leu Ile Tyr225 230 235
240Arg Met His Leu Asn Leu Glu Val Leu Tyr Cys His Val Tyr Leu Val
245 250 255Cys Met Ser Leu Ser Ser Leu Asn Ser Ser Ala Asn Pro Ile
Ile Tyr 260 265 270Phe Phe Val Gly Ser Phe Arg Gln Arg Gln Asn Arg
Gln Asn Leu Lys 275 280 285Leu Val Leu Gln Arg Ala Leu Gln Asp Lys
Pro Glu Val Asp Lys Gly 290 295 300Glu Gly Gln Leu Pro Glu Glu Ser
Leu Glu Leu Ser Gly Arg Arg Leu305 310 315 320Gly Pro12969DNAHomo
sapiens 12atggatccaa ccgtcccagt cttgggtaca aaactgacac caatcaacgg
acgtgaggag 60actccttgct acaagcagac cctgagcttc acggtgctga cgtgcatcat
ttcccttgtc 120ggactgacag gaaacgcggt tgtgctctgg ctcctgggct
gccgcatgcg caggaacgct 180gtctccatct acatcctcaa cctggccgca
gcagacttcc tcttcctcag cttccaaatt 240atacgttcgc cattacgcct
catcaatatc agccatctca tccgcaaaat cctcgtttct 300gtgatgacct
ttccctactt tacaggcctg agtatgctga gcgccatcag caccgagcgc
360tgcctgtctg ttctgtggcc catctggtac cgctgccgcc gccccacaca
cctgtcagcg 420gtcgtgtgtg tcctgctctg gggcctgtcc ctgctgttta
gtatgctgga gtggaggttc 480tgtgacttcc tgtttagtgg tgctgattct
agttggtgtg aaacgtcaga tttcatccca 540gtcgcgtggc tgattttttt
atgtgtggtt ctctgtgttt ccagcctggt cctgctggtc 600aggatcctct
gtggatcccg gaagatgccg ctgaccaggc tgtatgtgac catcctgctc
660acagtgctgg tcttcctcct ctgcggcctg cccttcggca ttctgggggc
cctaatttac 720aggatgcacc tgaatttgga agtcttatat tgtcatgttt
atctggtttg catgtccctg 780tcctctctaa acagtagtgc caaccccatc
atttacttct tcgtgggctc ctttaggcag 840cgtcaaaata ggcagaacct
gaagctggtt ctccagaggg ctctgcagga caagcctgag 900gtggataaag
gtgaagggca gcttcctgag gaaagcctgg agctgtcggg aaggagattg 960gggccatga
96913322PRTHomo sapiens 13Met Asp Pro Thr Val Pro Val Phe Gly Thr
Lys Leu Thr Pro Ile Asn1 5 10 15Gly Arg Glu Glu Thr Pro Cys Tyr Asn
Gln Thr Leu Ser Phe Thr Val 20 25 30Leu Thr Cys Ile Ile Ser Leu Val
Gly Leu Thr Gly Asn Ala Val Val 35 40 45Leu Trp Leu Leu Gly Tyr Arg
Met Arg Arg Asn Ala Val Ser Ile Tyr 50 55 60Ile Leu Asn Leu Ala Ala
Ala Asp Phe Leu Phe Leu Ser Phe Gln Ile65 70 75 80Ile Arg Ser Pro
Leu Arg Leu Ile Asn Ile Ser His Leu Ile Arg Lys 85 90 95Ile Leu Val
Ser Val Met Thr Phe Pro Tyr Phe Thr Gly Leu Ser Met 100 105 110Leu
Ser Ala Ile Ser Thr Glu Arg Cys Leu Ser Val Leu Trp Pro Ile 115 120
125Trp Tyr Arg Cys Arg Arg Pro Thr His Leu Ser Ala Val Val Cys Val
130 135 140Leu Leu Trp Gly Leu Ser Leu Leu Phe Ser Met Leu Glu Trp
Arg Phe145 150 155 160Cys Asp Phe Leu Phe Ser Gly Ala Asp Ser Ser
Trp Cys Glu Thr Ser 165 170 175Asp Phe Ile Pro Val Val Trp Leu Ile
Phe Leu Cys Val Val Leu Cys 180 185 190Val Ser Ser Leu Val Leu Leu
Val Arg Ile Leu Cys Gly Ser Arg Lys 195 200 205Met Pro Leu Thr Arg
Leu Tyr Val Thr Ile Leu Leu Thr Val Leu Val 210 215 220Phe Leu Leu
Cys Gly Leu Pro Phe Gly Ile Leu Gly Ala Leu Ile Tyr225 230 235
240Arg Met His Leu Asn Leu Glu Val Leu Tyr Cys His Val Tyr Leu Val
245 250 255Cys Met Ser Leu Ser Ser Leu Asn Ser Ser Ala Asn Pro Ile
Ile Tyr 260 265 270Phe Phe Val Gly Ser Phe Arg Gln Arg Gln Asn Arg
Gln Asn Leu Lys 275 280 285Leu Val Leu Gln Arg Ala Leu Gln Asp Lys
Pro Glu Val Asp Lys Gly 290 295 300Glu Gly Gln Leu Pro Glu Glu Ser
Leu Glu Leu Ser Gly Ser Lys Leu305 310 315 320Gly Pro14969DNAHomo
sapiens 14atggatccaa ccgtcccagt cttcggtaca aaactgacac caatcaacgg
acgtgaggag 60actccttgct acaatcagac cctgagcttc acggtgctga cgtgcatcat
ttcccttgtc 120ggactgacag gaaacgcggt tgtgctctgg ctcctgggct
accgcatgcg caggaacgct 180gtctccatct acatcctcaa cctggccgca
gcagacttcc tcttcctcag cttccaaatt 240atacgttcgc cattacgcct
catcaatatc agccatctca tccgcaaaat cctcgtttct 300gtgatgacct
ttccctactt tacaggcctg agtatgctga gcgccatcag caccgagcgc
360tgcctgtctg ttctgtggcc catctggtac cgctgccgcc gccccacaca
cctgtcagcg 420gtcgtgtgtg tcctgctctg gggcctgtcc ctgctgttta
gtatgctgga gtggaggttc 480tgtgacttcc tgtttagtgg tgctgattct
agttggtgtg aaacgtcaga tttcatccca 540gtcgtgtggc tgattttttt
atgtgtggtt ctctgtgttt ccagcctggt cctgctggtc 600aggatcctct
gtggatcccg gaagatgccg ctgaccaggc tgtacgtgac catcctgctc
660acagtgctgg tcttcctcct ctgcggcctg cccttcggca ttctgggggc
cctaatttac 720aggatgcacc tgaatttgga agtcttatat tgtcatgttt
atctggtttg catgtccctg 780tcctctctaa acagtagtgc caaccccatc
atttacttct tcgtgggctc ctttaggcag 840cgtcaaaata ggcagaacct
gaagctggtt ctccaaaggg ctctgcagga caagcctgag 900gtggataaag
gtgaagggca gcttcctgag gaaagcctgg agctgtcggg aagcaaattg 960gggccatga
9691535DNAartificial sequencesynthetic PCR primer 15ggccgtcgac
ttcatcgtcw myctnkcnyt ngcng 351615DNAartificial sequencesynthetic
PCR primer 16rhwrcartan atnat 151725DNAartificial sequencesynthetic
PCR primer 17cgcagatgag gtagtacagc 251825DNAartificial
sequencesynthetic PCR primer 18ctgtgagaga gatggtaaca
251924DNAartificial sequencesynthetic PCR primer 19gcatccttga
ctggttcttc tcag 242025DNAartificial sequencesynthetic PCR primer
20gggtgagact catcatcatt tgtgg 252130DNAartificial sequencesynthetic
PCR primer 21gcaagctttc tgagcatgga tccaaccgtc 302230DNAartificial
sequencesynthetic PCR primer 22ccctcagatc tccaatttgc ttcccgacag
30
* * * * *